VANDA PHARMACEUTICALS INC
NASDAQ: VNDA (Vanda Pharmaceuticals Inc.)
Last update: 44 minutes ago5.04
-0.21 (-4.00%)
| Previous Close | 5.25 |
| Volume | 956,724 |
| Price / Earnings (Forward) | 103.09 |
| Price / Sales | 1.45 |
| Price / Book | 1.44 |
| 52 Weeks Range |
| Profit Margin | -21.98% |
| Operating Margin (TTM) | -81.99% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Total Debt/Equity (MRQ) | 2.30% |
| Current Ratio (MRQ) | 3.92 |
| Operating Cash Flow (TTM) | -56.47 M |
| Levered Free Cash Flow (TTM) | -41.71 M |
| Return on Assets (TTM) | -7.05% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vanda Pharmaceuticals Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | 0.5 |
| Average | -1.67 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 78.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aqr Capital Management Llc | 30 Jun 2026 | 3,497,695 |
| Renaissance Technologies Llc | 30 Jun 2026 | 3,441,361 |
| Aigh Capital Management Llc | 30 Jun 2026 | 2,044,169 |
| Acadian Asset Management Llc | 30 Jun 2026 | 1,918,063 |
| Marshall Wace, Llp | 30 Jun 2026 | 1,225,996 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,213,326 |
| Krensavage Asset Management, Llc | 30 Jun 2026 | 1,180,388 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |